CVS Health Inc. (NYSE:CVS) on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to biosimilar medications, announcing new formulary changes that will take effect in 2026.

Beginning April 1, 2026, CVS Caremark will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide products Bonsity and Tymlos, to major national commercial template formularies.

These medications will replace the branded drugs Amgen Inc.’s (NASDAQ:AMGN) Prolia (denosumab) and Eli Lilly and Co.’s (NYSE:LLY) Forteo (teriparatide), which CVS Health said will result in costs that are more than 50% lower per prescription compared with the original brands.

CVS Caremark said the newly added biosimilars Ospomyv, from Cordavis Limited, and Stoboclo, from ...